Your Cholesterol Is High. Your Genes May Be Why.

APOE is your body’s master regulator of lipoprotein metabolism. This gene produces a protein that binds to LDL particles and signals your liver to pull them out of the bloodstream. Think of ApoE as the shipping label on cholesterol parcels. Without it, your liver can’t recognize which particles to clear, and LDL accumulates.

The APOE gene comes in three main variants: e2, e3, and e4. The e4 variant, carried by approximately 25% of people with European ancestry, fundamentally changes how efficiently your liver clears LDL. People with the e4 allele have reduced LDL receptor activity, meaning their cells take up LDL more slowly and leave it circulating in the bloodstream longer. This isn’t a rare mutation. It’s common. And it’s one of the strongest genetic predictors of elevated cholesterol and cardiovascular disease risk.

If you carry APOE e4, you likely noticed that your cholesterol responds sluggishly to diet changes that work for friends. Your LDL stays elevated even when you’re strict about fat intake. This is because your liver’s capacity to clear LDL particles is genetically limited, not a failure of willpower.

PCSK9 is your body’s recycling manager for LDL receptors. Normally, PCSK9 protein binds to LDL receptors on your liver cells and signals them to be destroyed and recycled. This is a healthy process in balance. But when you carry a gain-of-function variant in PCSK9, the recycling process accelerates dramatically. Your liver destroys LDL receptors faster than it replaces them.

Gain-of-function PCSK9 variants are present in roughly 1-3% of the population, but their effect on cholesterol is severe. People with gain-of-function PCSK9 variants have fewer functional LDL receptors on their liver cells, which means they cannot clear LDL from the blood efficiently. Statins work by upregulating LDL receptors, but if PCSK9 is destroying them faster than statins can build them, your LDL stays trapped in circulation.

You might notice that standard statin doses barely move your cholesterol. Your doctor keeps increasing the dose, and you see minimal improvement. This is the PCSK9 pattern. Your LDL isn’t high because you’re eating poorly. It’s high because your liver is systematically destroying the machinery that would clear it.

LDLR is the primary gateway for LDL removal from your bloodstream. Your liver cells display LDL receptors on their surface. When LDL particles circulate past, these receptors grab them and pull them inside the cell. The cholesterol is then processed, and the receptor is recycled back to the cell surface to grab more. This cycle happens thousands of times per day in a healthy liver.

Pathogenic variants in LDLR disrupt this recycling loop entirely. Familial hypercholesterolemia, caused by LDLR mutations, affects approximately 1 in 300 people in the general population. People with LDLR variants have dramatically impaired LDL clearance; their livers may clear only 20-50% of the LDL that a normal liver would process, regardless of diet or lifestyle. This isn’t a metabolic preference. It’s a structural deficiency. The receptor is missing, malformed, or non-functional.

If you have an LDLR variant, you’ve probably noticed cholesterol has been high since childhood or young adulthood. Your siblings or parents may also have early heart disease. Diet changes feel useless. Your LDL might be 200-400+ mg/dL even on a low-fat diet. This is the signature of a broken LDL receptor.

APOB is the structural protein on the surface of LDL particles. Think of it as the address label on a delivery package. When APOB is present and functional, LDL receptors can recognize and bind to the particle. Without proper APOB, the LDL particle is invisible to receptors. It circulates indefinitely.

Pathogenic variants in APOB (such as R3527Q) prevent the APOB protein from binding effectively to LDL receptors. Roughly 5% of familial hypercholesterolemia cases are caused by APOB mutations. People with APOB variants have LDL particles that their liver receptors literally cannot see or grab, leaving cholesterol trapped in the bloodstream despite having normal receptor function. This is a different problem than LDLR or PCSK9 variants, but the result is identical: LDL accumulates.

If you have an APOB variant, you experience the same clinical picture as LDLR deficiency: high cholesterol from early in life, resistance to diet, and minimal response to standard statins. The difference is mechanistic, but your lived experience is the same: your LDL numbers don’t move, and you wonder why.

CETP is the cholesteryl ester transfer protein. It shuttles HDL (good cholesterol) and LDL particles around, redistributing cholesterol between them. In people with normal CETP function, this protein moves protective HDL cholesterol and shifts it toward other particles. It’s a balancing act that evolved to manage cholesterol distribution.

CETP variants (such as TaqIB and I405V) reduce CETP activity. Approximately 40% of the population carries a CETP variant that lowers enzyme function. People with reduced CETP activity have higher HDL cholesterol and lower LDL cholesterol, but their LDL particles shift toward a smaller, denser subtype that may be more atherogenic (damaging to blood vessels). So the standard cholesterol numbers look better. But particle composition matters. Smaller, denser LDL particles are stickier and more prone to lodging in artery walls.

You might have been told your HDL is great and your total cholesterol isn’t terrible, so you’re low-risk. But if you carry a CETP variant, that particle composition shift means your real cardiovascular risk might be higher than the basic lipid panel suggests. You look good on paper but feel concerned about your actual heart health.

Lipoprotein(a), abbreviated Lp(a), is a particle similar to LDL but with an additional protein attached: apolipoproein(a). Your body produces Lp(a) regardless of diet. It circulates in your blood and contributes to cardiovascular risk independently. Unlike LDL, which you can influence with diet and statins, Lp(a) is almost entirely genetically determined.

LPA gene variants determine your baseline Lp(a) level. Approximately 20% of the population has elevated Lp(a) (above 50 mg/dL), and this elevation is almost purely genetic. People with high Lp(a) have a strongly elevated cardiovascular risk; elevated Lp(a) is as predictive of heart disease as high LDL cholesterol, but it doesn’t respond to standard statins or diet changes. Your cardiologist may never have measured your Lp(a). Most don’t. But if your number is high, it’s contributing silently to your risk.

You might have normal LDL cholesterol and still worry about your heart. Your family has a history of early heart attacks, but your standard cholesterol panel looks reasonable. You feel like something is off but can’t identify it. Elevated Lp(a) is often the missing piece. It’s genetic, invisible on basic bloodwork, and frequently overlooked.